Ko W.-C.Rolain J.-M.Lee N.-Y.Chen P.-L.Huang C.-T.PING-ING LEEPO-REN HSUEH2020-03-272020-03-2720200924-8579https://scholars.lib.ntu.edu.tw/handle/123456789/479659[SDGs]SDG3aciclovir; aristeromycin; favipiravir; galidesivir; penciclovir; remdesivir; ribavirin; RNA directed RNA polymerase; adenosine phosphate; alanine; antivirus agent; DNA directed RNA polymerase; remdesivir; amino acid substitution; antibiotic resistance; antiviral activity; clinical effectiveness; concentration response; coronavirus disease 2019; coronavirus disease 2019; Coronavirus infection; drug half life; drug tolerability; Ebola hemorrhagic fever; Editorial; human; nonhuman; priority journal; protein targeting; SARS-related coronavirus; Severe acute respiratory syndrome coronavirus 2; treatment outcome; treatment response; virus load; animal; Betacoronavirus; clinical trial (topic); Coronavirus infection; drug effect; enzymology; pandemic; virus pneumonia; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; DNA-Directed RNA Polymerases; Humans; Pandemics; Pneumonia, Viraleditorial10.1016/j.ijantimicag.2020.105933321475162-s2.0-85081899519